pioglitazone Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
peroxisome proliferator activating receptor-gamma (PPAR-gamma) agonists, thiazolidinedione derivatives	2179	111025-46-8

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: pioglitazone glustin sepioglin pioglitazone hydrochloride pioglitazone HCl	Pioglitazone is a thiazolidinedione that depends on the presence of insulin for its mechanism of action. Pioglitazone decreases insulin resistance in the periphery and in the liver resulting in increased insulin-dependent glucose disposal and decreased hepatic glucose output. Pioglitazone is not an insulin secretagogue. Pioglitazone is an agonist for peroxisome proliferator-activated receptor-gamma (PPAR-gamma). PPAR receptors are found in tissues important for insulin action such as adipose tissue, skeletal muscle, and liver. Activation of PPAR-gamma nuclear receptors modulates the transcription of a number of insulin responsive genes involved in the control of glucose and lipid metabolism. Molecular weight: 356.44 Formula: C19H20N2O3S CLOGP: 3.53 LIPINSKI: 0 HAC: 5 HDO: 1 TPSA: 68.29 ALOGS: -4.91 ROTB: 7 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

pioglitazone
glustin
sepioglin
pioglitazone hydrochloride
pioglitazone HCl

Pioglitazone is a thiazolidinedione that depends on the presence of insulin for its mechanism of action. Pioglitazone decreases insulin resistance in the periphery and in the liver resulting in increased insulin-dependent glucose disposal and decreased hepatic glucose output. Pioglitazone is not an insulin secretagogue. Pioglitazone is an agonist for peroxisome proliferator-activated receptor-gamma (PPAR-gamma). PPAR receptors are found in tissues important for insulin action such as adipose tissue, skeletal muscle, and liver. Activation of PPAR-gamma nuclear receptors modulates the transcription of a number of insulin responsive genes involved in the control of glucose and lipid metabolism.

Molecular weight: 356.44
Formula: C19H20N2O3S
CLOGP: 3.53
LIPINSKI: 0
HAC: 5
HDO: 1
TPSA: 68.29
ALOGS: -4.91
ROTB: 7

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
30	mg	O

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	2	Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine)	0.50 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	1.80 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability)	83 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H

Approvals:

Date	Agency	Company	Orphan
July 15, 1999	FDA	TAKEDA PHARMS USA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Bladder cancer	954.44	33.71	143	1499	581	2355862
Hypoglycaemia	425.19	33.71	108	1534	8299	2348144
Weight increased	402.51	33.71	128	1514	22209	2334234
Cardiac failure congestive	338.53	33.71	104	1538	15997	2340446
Oedema peripheral	334.10	33.71	113	1529	23650	2332793
Dyspnoea	237.58	33.71	125	1517	78608	2277835
Blood glucose increased	210.23	33.71	68	1574	12222	2344221
Cardiac failure	194.99	33.71	64	1578	12030	2344413
Drug hypersensitivity	165.72	33.71	83	1559	46560	2309883
Oedema	164.36	33.71	54	1588	10149	2346294
Diabetic metabolic decompensation	157.84	33.71	25	1617	150	2356293
Fall	156.13	33.71	80	1562	47019	2309424
Diabetes mellitus inadequate control	155.08	33.71	36	1606	1851	2354592
Bladder transitional cell carcinoma	116.71	33.71	18	1624	88	2356355
Lactic acidosis	113.76	33.71	35	1607	5295	2351148
Blood glucose decreased	102.97	33.71	29	1613	3223	2353220
Glycosylated haemoglobin increased	94.31	33.71	24	1618	1810	2354633
Fluid retention	92.39	33.71	32	1610	7014	2349429
Macular oedema	92.33	33.71	21	1621	981	2355462
Chest pain	79.20	33.71	43	1599	28094	2328349
Dyspnoea exertional	78.93	33.71	27	1615	5693	2350750
Haematuria	78.08	33.71	25	1617	4293	2352150
Dizziness	72.14	33.71	53	1589	58612	2297831
Tibia fracture	69.52	33.71	16	1626	787	2355656
Hyperglycaemia	67.15	33.71	23	1619	4862	2351581
Bladder neoplasm	62.37	33.71	11	1631	135	2356308
Suicide attempt	61.12	33.71	27	1615	11255	2345188
Condition aggravated	61.05	33.71	38	1604	31941	2324502
Pleural effusion	60.25	33.71	27	1615	11641	2344802
Shock	59.54	33.71	20	1622	3984	2352459
Asthenia	54.46	33.71	41	1601	46885	2309558
Renal impairment	54.16	33.71	24	1618	10068	2346375
Acute kidney injury	52.59	33.71	33	1609	28089	2328354
Ureteric cancer	50.91	33.71	8	1634	45	2356398
Myocardial infarction	50.49	33.71	28	1614	18985	2337458
Malaise	48.33	33.71	41	1601	55544	2300899
Cardiomegaly	47.96	33.71	15	1627	2381	2354062
Nausea	47.72	33.71	56	1586	112133	2244310
Hypoglycaemic coma	47.50	33.71	11	1631	555	2355888
Abdominal pain	46.55	33.71	33	1609	34341	2322102
Anaemia	46.19	33.71	33	1609	34759	2321684
Vomiting	44.98	33.71	44	1598	71558	2284885
Weight decreased	44.93	33.71	30	1612	28341	2328102
Incorrect dose administered	42.39	33.71	20	1622	9675	2346768
Diabetic retinopathy	41.42	33.71	9	1633	339	2356104
Urinary tract infection	41.11	33.71	29	1613	29913	2326530
Pulmonary oedema	41.07	33.71	18	1624	7345	2349098
Tachypnoea	40.65	33.71	13	1629	2216	2354227
Intentional overdose	39.44	33.71	20	1622	11301	2345142
Treatment noncompliance	39.08	33.71	16	1626	5518	2350925
Product dispensing error	38.98	33.71	13	1629	2528	2353915
Fatigue	38.74	33.71	44	1598	84829	2271614
Medication error	37.50	33.71	16	1626	6115	2350328
Headache	37.32	33.71	42	1600	80137	2276306
Pain	35.09	33.71	36	1606	61821	2294622
Tachycardia	35.08	33.71	21	1621	16388	2340055
Acute pulmonary oedema	34.27	33.71	10	1632	1253	2355190
Respiratory arrest	34.11	33.71	15	1627	6163	2350280

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Bladder cancer	4254.20	38.44	667	1773	1389	1742952
Bladder transitional cell carcinoma	760.67	38.44	123	2317	283	1744058
Haematuria	347.64	38.44	110	2330	7450	1736891
Oedema peripheral	333.60	38.44	128	2312	15422	1728919
Cardiac failure congestive	328.63	38.44	126	2314	15144	1729197
Hypoglycaemia	272.11	38.44	94	2346	8344	1735997
Weight increased	209.46	38.44	84	2356	11273	1733068
Blood glucose increased	156.77	38.44	67	2373	10517	1733824
Dyspnoea	152.19	38.44	113	2327	51946	1692395
Cardiac failure	151.85	38.44	69	2371	12533	1731808
Oedema	136.93	38.44	54	2386	6894	1737447
Transitional cell carcinoma	121.06	38.44	25	2415	285	1744056
Bladder neoplasm	114.48	38.44	24	2416	296	1744045
Macular oedema	111.79	38.44	28	2412	788	1743553
Diabetes mellitus inadequate control	106.22	38.44	32	2408	1810	1742531
Prostate cancer	91.21	38.44	36	2404	4590	1739751
Pulmonary oedema	88.54	38.44	39	2401	6547	1737794
Completed suicide	74.86	38.44	47	2393	16265	1728076
Myocardial infarction	70.12	38.44	55	2385	27119	1717222
Glycosylated haemoglobin increased	64.30	38.44	22	2418	1869	1742472
Ureteric cancer	61.37	38.44	11	2429	54	1744287
Bladder cancer recurrent	61.16	38.44	12	2428	103	1744238
Condition aggravated	57.09	38.44	44	2396	21106	1723235
Blood glucose decreased	52.55	38.44	20	2420	2305	1742036
Drug hypersensitivity	50.98	38.44	36	2404	15099	1729242
Fall	49.36	38.44	45	2395	27169	1717172
Pleural effusion	48.37	38.44	31	2409	11079	1733262
Fluid retention	46.16	38.44	21	2419	3788	1740553
Cardiomegaly	45.38	38.44	18	2422	2316	1742025
Anaemia	44.44	38.44	44	2396	29413	1714928
Diabetic retinopathy	43.20	38.44	11	2429	330	1744011
Pollakiuria	41.33	38.44	18	2422	2928	1741413
Dysuria	40.61	38.44	19	2421	3653	1740688
Loss of consciousness	40.20	38.44	31	2409	14844	1729497
Chest pain	40.18	38.44	35	2405	19879	1724462
Pancreatic carcinoma	39.52	38.44	15	2425	1714	1742627
Renal cyst	38.89	38.44	13	2427	1027	1743314

Pharmacologic Action:

Source	Code	Description
ATC	A10BG03	ALIMENTARY TRACT AND METABOLISM DRUGS USED IN DIABETES BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS Thiazolidinediones
ATC	A10BD05	ALIMENTARY TRACT AND METABOLISM DRUGS USED IN DIABETES BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS Combinations of oral blood glucose lowering drugs
ATC	A10BD06	ALIMENTARY TRACT AND METABOLISM DRUGS USED IN DIABETES BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS Combinations of oral blood glucose lowering drugs
ATC	A10BD09	ALIMENTARY TRACT AND METABOLISM DRUGS USED IN DIABETES BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS Combinations of oral blood glucose lowering drugs
ATC	A10BD12	ALIMENTARY TRACT AND METABOLISM DRUGS USED IN DIABETES BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS Combinations of oral blood glucose lowering drugs
MeSH PA	D007004	Hypoglycemic Agents
CHEBI has role	CHEBI:50864	insulin-sensitizing drug
FDA EPC	N0000175596	Peroxisome Proliferator Receptor alpha Agonist
FDA EPC	N0000180186	Peroxisome Proliferator Receptor gamma Agonist
FDA MoA	N0000175374	Peroxisome Proliferator-activated Receptor Activity
FDA CS	M0199111	PPAR alpha
FDA CS	M0199114	PPAR gamma
FDA EPC	N0000180190	Thiazolidinedione
FDA CS	M0447306	Thiazolidinediones

Drug Use (View source of the data)

Disease	Relation	SNOMED_ID	DOID
Diabetes mellitus type 2	indication	44054006	DOID:9352
Alcoholism	contraindication	7200002
Asthenia	contraindication	13791008
Myocardial infarction	contraindication	22298006	DOID:5844
Acute vomiting	contraindication	23971007
Alcohol intoxication	contraindication	25702006
Shock	contraindication	27942005
Dehydration	contraindication	34095006
Macular retinal edema	contraindication	37231002	DOID:4449
Infectious disease	contraindication	40733004
Body fluid retention	contraindication	43498006
Chronic heart failure	contraindication	48447003
Hepatic porphyria	contraindication	55056006	DOID:3133
Ketoacidosis	contraindication	56051008
Metabolic acidosis	contraindication	59455009
Hemolytic anemia	contraindication	61261009	DOID:583
Glucose-6-phosphate dehydrogenase deficiency anemia	contraindication	62403005
Hypopituitarism	contraindication	74728003	DOID:9406
Cardiogenic shock	contraindication	89138009
Kidney disease	contraindication	90708001	DOID:557
Lactic acidosis	contraindication	91273001	DOID:3650
Fracture of bone	contraindication	125605004
Autonomic dysreflexia	contraindication	129618003
Liver function tests abnormal	contraindication	166603001
Cobalamin deficiency	contraindication	190634004
Decompensated cardiac failure	contraindication	195111005
Disease of liver	contraindication	235856003	DOID:409
Hypoglycemic disorder	contraindication	237630007
Sepsis syndrome	contraindication	238150007
Edema	contraindication	267038008
Primary adrenocortical insufficiency	contraindication	373662000
Adrenal cortical hypofunction	contraindication	386584007	DOID:10493
Fever	contraindication	386661006
Surgical procedure	contraindication	387713003
Malignant tumor of urinary bladder	contraindication	399326009	DOID:11054
Severe diarrhea	contraindication	409587002
Breastfeeding (mother)	contraindication	413712001
Traumatic injury	contraindication	417746004
Fever greater than 100.4 Fahrenheit	contraindication	426000000
Radiography with IV Iodinated Contrast Agent	contraindication
Severe Hypoxemia	contraindication

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	6.33	acidic
pKa2	7.15	Basic

Orange Book patent data (new drug applications)

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Patent number	Patent expiration date	Patent use
EQ 15MG BASE	ACTOPLUS MET XR	TAKEDA PHARMS USA	N022024	May 12, 2009	DISCN	TABLET, EXTENDED RELEASE	ORAL	6790459	March 17, 2021	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES WHO ARE ALREADY TREATED WITH A PIOGLITAZONE AND METFORMIN
EQ 30MG BASE	ACTOPLUS MET XR	TAKEDA PHARMS USA	N022024	May 12, 2009	DISCN	TABLET, EXTENDED RELEASE	ORAL	6790459	March 17, 2021	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES WHO ARE ALREADY TREATED WITH A PIOGLITAZONE AND METFORMIN
EQ 15MG BASE	OSENI	TAKEDA PHARMS USA	N022426	Jan. 25, 2013	RX	TABLET	ORAL	6329404	June 19, 2021	METHODS OF TREATING DIABETES COMPRISING ADMINISTERING AN INSULIN SENSITIVITY ENHANCER SUCH AS PIOGLITAZONE IN COMBINATION WITH AN INSULIN SECRETION ENHANCER
EQ 30MG BASE	OSENI	TAKEDA PHARMS USA	N022426	Jan. 25, 2013	RX	TABLET	ORAL	6329404	June 19, 2021	METHODS OF TREATING DIABETES COMPRISING ADMINISTERING AN INSULIN SENSITIVITY ENHANCER SUCH AS PIOGLITAZONE IN COMBINATION WITH AN INSULIN SECRETION ENHANCER
EQ 45MG BASE	OSENI	TAKEDA PHARMS USA	N022426	Jan. 25, 2013	RX	TABLET	ORAL	6329404	June 19, 2021	METHODS OF TREATING DIABETES COMPRISING ADMINISTERING AN INSULIN SENSITIVITY ENHANCER SUCH AS PIOGLITAZONE IN COMBINATION WITH AN INSULIN SECRETION ENHANCER
EQ 15MG BASE	OSENI	TAKEDA PHARMS USA	N022426	Jan. 25, 2013	RX	TABLET	ORAL	8173663	March 15, 2025	METHOD OF TREATING DIABETES COMPRISING ADMINISTERING A COMPOUND SUCH AS ALOGLIPTIN
EQ 30MG BASE	OSENI	TAKEDA PHARMS USA	N022426	Jan. 25, 2013	RX	TABLET	ORAL	8173663	March 15, 2025	METHOD OF TREATING DIABETES COMPRISING ADMINISTERING A COMPOUND SUCH AS ALOGLIPTIN
EQ 45MG BASE	OSENI	TAKEDA PHARMS USA	N022426	Jan. 25, 2013	RX	TABLET	ORAL	8173663	March 15, 2025	METHOD OF TREATING DIABETES COMPRISING ADMINISTERING A COMPOUND SUCH AS ALOGLIPTIN
EQ 15MG BASE	OSENI	TAKEDA PHARMS USA	N022426	Jan. 25, 2013	RX	TABLET	ORAL	7807689	June 27, 2028	METHOD OF TREATING DIABETES COMPRISING ADMINISTERING ALOGLIPTIN
EQ 30MG BASE	OSENI	TAKEDA PHARMS USA	N022426	Jan. 25, 2013	RX	TABLET	ORAL	7807689	June 27, 2028	METHOD OF TREATING DIABETES COMPRISING ADMINISTERING ALOGLIPTIN
EQ 45MG BASE	OSENI	TAKEDA PHARMS USA	N022426	Jan. 25, 2013	RX	TABLET	ORAL	7807689	June 27, 2028	METHOD OF TREATING DIABETES COMPRISING ADMINISTERING ALOGLIPTIN

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Peroxisome proliferator-activated receptor gamma	Nuclear hormone receptor	P37231	PPARG_HUMAN	AGONIST	EC50	6.23	WOMBAT-PK	CHEMBL
Carbonic anhydrase 2	Enzyme	P00918	CAH2_HUMAN		IC50	6.94	DRUG MATRIX
Amine oxidase [flavin-containing] A	Enzyme	P21397	AOFA_HUMAN		IC50	4.46	DRUG MATRIX
Amine oxidase [flavin-containing] B	Enzyme	P27338	AOFB_HUMAN		Ki	6.30	CHEMBL
Peroxisome proliferator-activated receptor alpha	Nuclear hormone receptor	Q07869	PPARA_HUMAN		EC50	5.18	CHEMBL
Bile salt export pump	Transporter	O95342	ABCBB_HUMAN		IC50	6.52	CHEMBL
Aldose reductase	Enzyme		ALDR_RAT		IC50	4.88	DRUG MATRIX
Peroxisome proliferator-activated receptor gamma	Transcription factor		PPARG_MOUSE		IC50	6.15	CHEMBL
Enoyl-[acyl-carrier-protein] reductase [NADH]	Enzyme		Q5NGQ3_FRATT		IC50	4.10	CHEMBL
Amine oxidase [flavin-containing] B	Enzyme		AOFB_RAT		Ki	5.68	CHEMBL
Peroxisome proliferator-activated receptor gamma	Transcription factor		PPARG_RAT		IC50	6.15	CHEMBL
Bile salt export pump	Unclassified		ABCBB_RAT		IC50	5.70	CHEMBL

External reference:

ID	Source
D000077205	MESH_DESCRIPTOR_UI
4021165	VUID
N0000148616	NUI
C0071097	UMLSCUI
D00945	KEGG_DRUG
326058001	SNOMEDCT_US
4021165	VANDF
007823	NDDF
d04442	MMSL
33738	RXNORM
395828009	SNOMEDCT_US
29092	MMSL
CHEMBL595	ChEMBL_ID
DB01132	DRUGBANK_ID
CHEMBL1715	ChEMBL_ID
JQT35NPK6C	UNII
112529-15-4	SECONDARY_CAS_RN
8N6	PDB_CHEM_ID
P1B	PDB_CHEM_ID
CHEBI:8228	CHEBI
6343	INN_ID
4829	PUBCHEM_CID
2694	IUPHAR_LIGAND_ID

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Pioglitazone	HUMAN PRESCRIPTION DRUG LABEL	1	0093-7271	TABLET	15 mg	ORAL	ANDA	18 sections
Pioglitazone	HUMAN PRESCRIPTION DRUG LABEL	1	0093-7272	TABLET	30 mg	ORAL	ANDA	18 sections
Pioglitazone	HUMAN PRESCRIPTION DRUG LABEL	1	0093-7273	TABLET	45 mg	ORAL	ANDA	18 sections
Pioglitazone	HUMAN PRESCRIPTION DRUG LABEL	1	0781-5420	TABLET	15 mg	ORAL	ANDA	18 sections
Pioglitazone	HUMAN PRESCRIPTION DRUG LABEL	1	0781-5421	TABLET	30 mg	ORAL	ANDA	18 sections
Pioglitazone	HUMAN PRESCRIPTION DRUG LABEL	1	0781-5422	TABLET	45 mg	ORAL	ANDA	18 sections
Pioglitazone and metformin	HUMAN PRESCRIPTION DRUG LABEL	2	0781-5626	TABLET, FILM COATED	15 mg	ORAL	ANDA	19 sections
Pioglitazone and metformin	HUMAN PRESCRIPTION DRUG LABEL	2	0781-5627	TABLET, FILM COATED	15 mg	ORAL	ANDA	19 sections
Pioglitazone hydrochloride and glimepiride	HUMAN PRESCRIPTION DRUG LABEL	2	0781-5634	TABLET	30 mg	ORAL	ANDA	18 sections
Pioglitazone hydrochloride and glimepiride	HUMAN PRESCRIPTION DRUG LABEL	2	0781-5635	TABLET	30 mg	ORAL	ANDA	18 sections
PIOGLITAZONEHYDROCHLORIDE	HUMAN PRESCRIPTION DRUG LABEL	1	13668-119	TABLET	30 mg	ORAL	ANDA	19 sections
PIOGLITAZONEHYDROCHLORIDE	HUMAN PRESCRIPTION DRUG LABEL	1	13668-120	TABLET	45 mg	ORAL	ANDA	19 sections
PIOGLITAZONEHYDROCHLORIDE	HUMAN PRESCRIPTION DRUG LABEL	1	13668-140	TABLET	15 mg	ORAL	ANDA	19 sections
Pioglitazone HCL and Metformin HCL	HUMAN PRESCRIPTION DRUG LABEL	2	13668-280	TABLET	15 mg	ORAL	ANDA	19 sections
Pioglitazone HCL and Metformin HCL	HUMAN PRESCRIPTION DRUG LABEL	2	13668-281	TABLET	15 mg	ORAL	ANDA	19 sections
PIOGLITAZONE	HUMAN PRESCRIPTION DRUG LABEL	1	16729-020	TABLET	15 mg	ORAL	ANDA	19 sections
PIOGLITAZONE	HUMAN PRESCRIPTION DRUG LABEL	1	16729-021	TABLET	30 mg	ORAL	ANDA	19 sections
PIOGLITAZONE	HUMAN PRESCRIPTION DRUG LABEL	1	16729-022	TABLET	45 mg	ORAL	ANDA	19 sections
Actos	HUMAN PRESCRIPTION DRUG LABEL	1	21695-147	TABLET	15 mg	ORAL	NDA	14 sections
Actos	HUMAN PRESCRIPTION DRUG LABEL	1	21695-148	TABLET	30 mg	ORAL	NDA	14 sections
Pioglitazone	HUMAN PRESCRIPTION DRUG LABEL	1	33342-054	TABLET	15 mg	ORAL	ANDA	19 sections
Pioglitazone	HUMAN PRESCRIPTION DRUG LABEL	1	33342-055	TABLET	30 mg	ORAL	ANDA	19 sections
Pioglitazone	HUMAN PRESCRIPTION DRUG LABEL	1	33342-056	TABLET	45 mg	ORAL	ANDA	19 sections
Pioglitazole and metformin hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	2	33342-176	TABLET	15 mg	ORAL	ANDA	19 sections
Pioglitazole and metformin hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	2	33342-177	TABLET	15 mg	ORAL	ANDA	19 sections
PIOGLITAZONE HYDROCHLORIDE	HUMAN PRESCRIPTION DRUG LABEL	1	43063-894	TABLET	15 mg	ORAL	ANDA	19 sections
PIOGLITAZONE HYDROCHLORIDE	HUMAN PRESCRIPTION DRUG LABEL	1	43063-895	TABLET	30 mg	ORAL	ANDA	19 sections
Pioglitazone Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	43353-326	TABLET	45 mg	ORAL	ANDA	19 sections
PIOGLITAZONE	HUMAN PRESCRIPTION DRUG LABEL	1	43547-426	TABLET	15 mg	ORAL	ANDA	19 sections
PIOGLITAZONE	HUMAN PRESCRIPTION DRUG LABEL	1	43547-427	TABLET	30 mg	ORAL	ANDA	19 sections